Walleye Capital
AKRO

Walleye Capital’s Akero Therapeutics AKRO Stock Holding History

Walleye Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,300
Closed -$109K – 4514
2025
Q3 		$109K Buy
+2,300
New +$111K ﹤0.01% 3670
2024
Q3 		– Sell
-3,300
Closed -$77.4K – 5205
2024
Q2 		$77.4K Buy
+3,300
New +$70.6K ﹤0.01% 4810
2024
Q1 		– Sell
-20,400
Closed -$476K – 5377
2023
Q4 		$476K Buy
+20,400
New +$402K ﹤0.01% 2991
2023
Q3 		– Sell
-8,100
Closed -$378K – 4820
2023
Q2 		$378K Buy
8,100
+7,400
+1,057% +$339K ﹤0.01% 2641
2023
Q1 		$26.8K Sell
700
-900
-56% -$40.1K ﹤0.01% 3339
2022
Q4 		$87.7K Buy
+1,600
New +$68.6K ﹤0.01% 2395

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's AKRO Position: Q3 2025 in Review

Walleye Capital sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 3,323 shares — an estimated $161K sold.

Walleye Capital first reported a position in AKRO in Q3 2022 and held it in 10 quarters. The position peaked at $6.95M in Q3 2022. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Walleye Capital reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 3,323 Akero Therapeutics shares in Q3 2025, an estimated $161K.
  • Walleye Capital first reported a position in Akero Therapeutics in Q3 2022 and held it in 10 quarters.
  • Walleye Capital's Akero Therapeutics position peaked at $6.95M in Q3 2022.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.